Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 191

The DOI matches its Crossref record.

Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS

Dupuis, Jehan, Berriolo-Riedinger, Alina, Julian, Anne, Brice, Pauline, Tychyj-Pinel, Christelle, Tilly, Hervé, Mounier, Nicolas, Gallamini, Andrea, Feugier, Pierre, Soubeyran, Pierre, Colombat, Philippe, Laurent, Guy, Berenger, Nathalie, Casasnovas, Rene-Olivier, Vera, Pierre, Paone, Gaetano, Xerri, Luc, Salles, Gilles, Haioun, Corinne, Meignan, Michel · 2012 · Journal of Clinical Oncology

Abstract

Purpose: [18 F]Fluorodeoxyglucose positron emission tomography (PET) is widely used for the staging and restaging of patients with aggressive lymphoma, but less is known about the utility of PET in patients with follicular lymphoma (FL). In a prospective study, we evaluated the prognostic value of PET performed during treatment and at the end of treatment in 121 patients with FL treated with first-line immunochemotherapy. Patients and Methods: Patients with previously untreated high–tumor burden FL were treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) plus two cycles of rituximab, without rituximab maintenance. PET was performed before treatment, after four cycles of R-CHOP (interim PET), and at the end of treatment (final PET). PET scans were centrally reviewed. Results: The total number of patients included was 121. Median age was 57 years. After central review, interim PET (n = 111) was negative in 76% of patients, and final PET (n = 106) was negative in 78%. With a median follow-up of 23 months, 2-year progression-free survival rates were 86% for interim PET–negative versus 61% for interim PET–positive patients (P = .0046) and 87% for final PET–negative versus 51% for final PET–positive patients (P < .001), respectively. Two-year overall survival also significantly differed according to final PET results: 100% versus 88% (P = .0128). Conclusion: PET performed either after four cycles of R-CHOP or at the end of therapy was strongly predictive of outcome in this prospective study. Therapeutic intervention based on PET results during or after inductive treatment should be evaluated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.43.0934

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 191

Metadata

Authors
Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., Colombat, P., Laurent, G., Berenger, N., Casasnovas, R.-O., Vera, P., Paone, G., Xerri, L., Salles, G., Haioun, C., & Meignan, M.
Venue
Journal of Clinical Oncology
Published
2012-12-10
Volume
30
Issue
35
Pages
4317-4322
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2097346190
Cited by
191
References
0
FWCI
11.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. https://app.cochat.ai/papers/10.1200/jco.2012.43.0934
The paper
Dupuis, J., Berriolo-Riedinger, A., Julian, A., Brice, P., Tychyj-Pinel, C., Tilly, H., Mounier, N., Gallamini, A., Feugier, P., Soubeyran, P., Colombat, P., Laurent, G., Berenger, N., Casasnovas, R.-O., Vera, P., Paone, G., Xerri, L., Salles, G., Haioun, C., & Meignan, M. (2012). Impact of [18F]Fluorodeoxyglucose Positron Emission Tomography Response Evaluation in Patients With High–Tumor Burden Follicular Lymphoma Treated With Immunochemotherapy: A Prospective Study From the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.43.0934

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.